Diagnostic kits and services
Cancer Panel Development and Service
For the past 5 years, we have applied technologies such as NGS, whole genome microarray-CGH, and whole genome miRNA array to discover genetic mutations that cause various solid and blood cancers and gene mutations that contribute to cancer progression, and has been announced these results in major scientific journals.
Although some of the self-developed cancer panels were made for their own use in some large domestic hospitals, Korean standard-type cancer panels that can support various medical institutions have not been developed.
Connectagen, in collaboration with the Catholic Center for Precision Medicine, developed two types of cancer panels that support both types of NGS.
This cancer panel is designed to detect gene mutations for most anticancer drug targets available worldwide. In addition, it was designed to analyze mutations such as genes whose clinical significance was newly revealed in recent studies, such as the TERT promoter, or mutations such as MSI, which were traditionally important but could not be tested with NGS for technical reasons.
Ankylosing Spondylitis Gene Analysis KIT
Ankylosing spondylitis (AS), a form of spondyloarthritis, is a chronic progressive systemic disease that usually begins in the late teens to early 20s and shows typical spinal stiffness in the 30s and 40s.
The patient is diagnosed by a doctor in a partially advanced state of spondyloarthritis, but with the current diagnostic criteria, the initial treatment point has already been missed and a cure is impossible.
If the diagnosis or onset of the disease is predicted at an early stage and appropriate treatment is provided, the disease progression can be delayed or cured.
Although the cause of the disease has not been clearly identified, the genotype "HLA-B27" is expected to be highly correlated.
However, the HLA-B27 test cannot be used to diagnose or predict the onset of the disease at an early stage.
The ankylosing spondylitis early test method developed by us is the world's first test method that combines four genetic tests in addition to HLA-B27 to help diagnose/predict the disease early and take an appropriate response.
The prevalence of ankylosing spondylitis in China is about 500 per 100,000, which is the highest in the world, and the demand for tests is between 2 and 5 million. The prevalence in Korea is 50 per 100,000, and the annual demand for testing is about 100,000.
Custom Health Design
We provide a personalized health design for each individual through genome analysis.
Functional foods and cosmetics of domestic and overseas partners can be analyzed with Connectagen's own specialized technology.
